Cara Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
11,964.00
3,177.00
3,803.00
86.00
911.00
13,469
SG&A Expense
11,377.00
20,466.00
28,152.00
57,021.00
59,901.00
90,481
EBIT
202.00
18,072.00
25,188.00
58,400.00
59,485.00
77,382
Unusual Expense
35.00
-
-
-
-
-
Non Operating Income/Expense
-
-
-
23.00
5.00
5
Interest Expense
3,756.00
-
-
-
-
-
Pretax Income
3,993.00
17,946.00
25,087.00
57,748.00
58,329.00
74,402
Income Tax
30.00
201.00
397.00
468.00
204.00
389
Consolidated Net Income
3,072.00
17,745.00
24,690.00
57,280.00
58,125.00
74,013
Net Income
3,072.00
17,745.00
24,690.00
57,280.00
58,125.00
74,013
Net Income After Extraordinaries
3,072.00
17,745.00
24,690.00
57,280.00
58,125.00
74,013
Net Income Available to Common
3,072.00
17,745.00
24,690.00
57,280.00
58,125.00
74,013
EPS (Basic)
0.74
0.85
1.00
2.10
1.86
2.06
Basic Shares Outstanding
4,133.10
20,965.90
24,620.40
27,279.00
31,202.80
35,892.80
EPS (Diluted)
0.74
0.85
1.00
2.10
1.86
2.06
Diluted Shares Outstanding
4,133.10
20,965.90
24,620.40
27,279.00
31,202.80
35,892.80
EBITDA
587.00
17,289.00
24,349.00
56,935.00
58,990.00
77,012
Non-Operating Interest Income
-
126.00
101.00
629.00
1,151.00
2,985
Other After Tax Income (Expense)
891.00
-
-
-
-
-
About Cara Therapeutics
View Profile
